Bristol Myers Squibb (NYSE: BMY) announced positive topline results from its Phase 2 QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE